ATE407935T1 - Thieno(3,2-d)pyrimidine und furano(3,2- d)pyrimidine und deren verwendung als antagonisten an purinergen rezeptoren - Google Patents

Thieno(3,2-d)pyrimidine und furano(3,2- d)pyrimidine und deren verwendung als antagonisten an purinergen rezeptoren

Info

Publication number
ATE407935T1
ATE407935T1 AT02729449T AT02729449T ATE407935T1 AT E407935 T1 ATE407935 T1 AT E407935T1 AT 02729449 T AT02729449 T AT 02729449T AT 02729449 T AT02729449 T AT 02729449T AT E407935 T1 ATE407935 T1 AT E407935T1
Authority
AT
Austria
Prior art keywords
sub
conr
alkyl
aryl
cor
Prior art date
Application number
AT02729449T
Other languages
English (en)
Inventor
Roger John Gillespie
Joanne Lerpiniere
Claire Elizabeth Dawson
Suneel Gaur
Robert Mark Pratt
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Application granted granted Critical
Publication of ATE407935T1 publication Critical patent/ATE407935T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02729449T 2001-01-10 2002-01-10 Thieno(3,2-d)pyrimidine und furano(3,2- d)pyrimidine und deren verwendung als antagonisten an purinergen rezeptoren ATE407935T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0100620.4A GB0100620D0 (en) 2001-01-10 2001-01-10 Chemical cokpounds V

Publications (1)

Publication Number Publication Date
ATE407935T1 true ATE407935T1 (de) 2008-09-15

Family

ID=9906567

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02729449T ATE407935T1 (de) 2001-01-10 2002-01-10 Thieno(3,2-d)pyrimidine und furano(3,2- d)pyrimidine und deren verwendung als antagonisten an purinergen rezeptoren

Country Status (8)

Country Link
US (2) US7384949B2 (de)
EP (1) EP1349861B1 (de)
JP (1) JP4390454B2 (de)
AT (1) ATE407935T1 (de)
CA (1) CA2434005A1 (de)
DE (1) DE60228817D1 (de)
GB (1) GB0100620D0 (de)
WO (1) WO2002055524A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101098209B1 (ko) 2002-01-28 2011-12-23 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법
WO2003070241A1 (en) 2002-02-15 2003-08-28 Rigel Pharmaceuticals, Inc. Inhibitors of tubulin polymerization
JP2004137270A (ja) * 2002-09-26 2004-05-13 Nippon Nohyaku Co Ltd 新規除草剤、その使用方法、新規置換チエノピリミジン誘導体及びその中間体並びにそれらの製造方法
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
WO2006137350A1 (ja) * 2005-06-22 2006-12-28 Kissei Pharmaceutical Co., Ltd. 新規なフロピリジン誘導体、それを含有する医薬組成物およびそれらの用途
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
CA2644996A1 (en) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
KR20110040856A (ko) * 2008-07-23 2011-04-20 교와 핫꼬 기린 가부시키가이샤 편두통 치료제
US20100093763A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093702A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
RU2013120966A (ru) 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
EP2892534B8 (de) * 2012-09-06 2021-09-15 Plexxikon Inc. Verbindungen und verfahren zur kinasemodulation und indikationen dafür
WO2014111037A1 (zh) * 2013-01-18 2014-07-24 上海昀怡健康管理咨询有限公司 五元并六元杂环化合物、其制备方法、药物组合物和应用
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
JP2020532541A (ja) 2017-08-31 2020-11-12 コーバス・ファーマシューティカルズ・インコーポレイテッド アデノシンａ２ｂ受容体およびアデノシンａ２ａ受容体を調節するための化合物および方法
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US11787775B2 (en) * 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
WO2022129376A1 (en) * 2020-12-18 2022-06-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) 6-6 or 5-6 fused bicyclic compounds comprising a pyri(mi)dine ring useful in the|treatment of infectious diseases
EP4681774A3 (de) * 2021-03-29 2026-03-25 Gilead Sciences, Inc. Khk-hemmer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0436284A (ja) * 1990-05-29 1992-02-06 Sumitomo Chem Co Ltd ジフェニルフロピリミジン誘導体、その製造法およびそれを有効成分とする除草剤
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
EP0975345A1 (de) * 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine zur blockierung der purinrezeptoren und zur behandlung von bewegung- oder neurodegenerativen erkrankungen
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
GB9819384D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819382D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9915437D0 (en) * 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
WO2001062233A2 (en) 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators

Also Published As

Publication number Publication date
EP1349861B1 (de) 2008-09-10
DE60228817D1 (de) 2008-10-23
US7384949B2 (en) 2008-06-10
CA2434005A1 (en) 2002-07-18
US20040097524A1 (en) 2004-05-20
US20080153820A1 (en) 2008-06-26
EP1349861A1 (de) 2003-10-08
JP4390454B2 (ja) 2009-12-24
JP2004524293A (ja) 2004-08-12
WO2002055524A1 (en) 2002-07-18
GB0100620D0 (en) 2001-02-21

Similar Documents

Publication Publication Date Title
ATE407935T1 (de) Thieno(3,2-d)pyrimidine und furano(3,2- d)pyrimidine und deren verwendung als antagonisten an purinergen rezeptoren
ATE424207T1 (de) Triazoloä4,5-düpyrimidinderivate und ihre verwendung als antagonisten purinerger rezeptoren
ZA200305116B (en) Purine derivatives as purinergic receptor antagonists.
ATE405270T1 (de) Pyrrolo 2,3-d pyrimidine und deren verwendung als purinreceptor antagonisten
ATE307132T1 (de) Purin derivate als a2b adenosin rezeptor antagonisten
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
MXPA05010621A (es) Pirimidinonas sustituidas.
NZ702041A (en) Heterocyclic containing entities, compositions and methods
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
DE60022042D1 (de) Thieno- und furopyrimidin derivate als a2a-rezeptor antagonisten
DK1107973T3 (da) Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi
WO2004094431A3 (en) 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
ATE418555T1 (de) A2a-adenosinrezeptorantagonisten
WO2003068776A1 (en) [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties